272 related articles for article (PubMed ID: 37436975)
1. Artificial intelligence-coupled plasmonic infrared sensor for detection of structural protein biomarkers in neurodegenerative diseases.
Kavungal D; Magalhães P; Kumar ST; Kolla R; Lashuel HA; Altug H
Sci Adv; 2023 Jul; 9(28):eadg9644. PubMed ID: 37436975
[TBL] [Abstract][Full Text] [Related]
2. Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases.
Campese N; Beatino MF; Del Gamba C; Belli E; Giampietri L; Del Prete E; Galgani A; Vergallo A; Siciliano G; Ceravolo R; Hampel H; Baldacci F
Expert Rev Neurother; 2021 Sep; 21(9):949-967. PubMed ID: 34365867
[TBL] [Abstract][Full Text] [Related]
3. miRNAs as biomarkers of neurodegenerative disorders.
Viswambharan V; Thanseem I; Vasu MM; Poovathinal SA; Anitha A
Biomark Med; 2017 Feb; 11(2):151-167. PubMed ID: 28125293
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for neurodegenerative diseases.
Hansson O
Nat Med; 2021 Jun; 27(6):954-963. PubMed ID: 34083813
[TBL] [Abstract][Full Text] [Related]
5. Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases.
Tapia-Arellano A; Cabrera P; Cortés-Adasme E; Riveros A; Hassan N; Kogan MJ
J Nanobiotechnology; 2024 May; 22(1):248. PubMed ID: 38741193
[TBL] [Abstract][Full Text] [Related]
6. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
7. Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases.
Campese N; Palermo G; Del Gamba C; Beatino MF; Galgani A; Belli E; Del Prete E; Della Vecchia A; Vergallo A; Siciliano G; Ceravolo R; Hampel H; Baldacci F
Expert Rev Proteomics; 2021 Jan; 18(1):27-48. PubMed ID: 33545008
[No Abstract] [Full Text] [Related]
8. The role of basket trials in drug development for neurodegenerative disorders.
Cummings J; Montes A; Kamboj S; Cacho JF
Alzheimers Res Ther; 2022 May; 14(1):73. PubMed ID: 35614479
[TBL] [Abstract][Full Text] [Related]
9. miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.
Mushtaq G; Greig NH; Anwar F; Zamzami MA; Choudhry H; Shaik MM; Tamargo IA; Kamal MA
Med Chem; 2016; 12(3):217-25. PubMed ID: 26527155
[TBL] [Abstract][Full Text] [Related]
10. Exosomal microRNAs as diagnostic biomarkers and therapeutic applications in neurodegenerative diseases.
Sataer X; Qifeng Z; Yingying Z; Chunhua H; Bingzhenga F; Zhiran X; Wanli L; Yuwei Y; Shuangfeng C; Lingling W; Hongri H; Jibing C; Xiaoping R; Hongjun G
Neurol Res; 2023 Mar; 45(3):191-199. PubMed ID: 36184105
[TBL] [Abstract][Full Text] [Related]
11. Ultra-sensitive techniques for detecting neurological biomarkers: Prospects for early diagnosis.
Kumar D; Hassan MI
Biochem Biophys Res Commun; 2021 Dec; 584():15-18. PubMed ID: 34753063
[TBL] [Abstract][Full Text] [Related]
12. Morphometric and Nanomechanical Screening of Peripheral Blood Cells with Atomic Force Microscopy for Label-Free Assessment of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.
Taneva SG; Todinova S; Andreeva T
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762599
[TBL] [Abstract][Full Text] [Related]
13. Molecularly imprinted polymers for the recognition of biomarkers of certain neurodegenerative diseases.
Pilvenyte G; Ratautaite V; Boguzaite R; Samukaite-Bubniene U; Plausinaitis D; Ramanaviciene A; Bechelany M; Ramanavicius A
J Pharm Biomed Anal; 2023 May; 228():115343. PubMed ID: 36934618
[TBL] [Abstract][Full Text] [Related]
14. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.
Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M
Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435
[TBL] [Abstract][Full Text] [Related]
15. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.
Noelker C; Hampel H; Dodel R
Mol Diagn Ther; 2011 Apr; 15(2):83-102. PubMed ID: 21623645
[TBL] [Abstract][Full Text] [Related]
16. A review on the new age methodologies for early detection of Alzheimer's and Parkinson's disease.
Ghosh N; Sinha K; Sil PC
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):602-613. PubMed ID: 38482977
[TBL] [Abstract][Full Text] [Related]
17. Data-driven biomarker analysis using computational omics approaches to assess neurodegenerative disease progression.
Krokidis MG; Exarchos TP; Vlamos P
Math Biosci Eng; 2021 Feb; 18(2):1813-1832. PubMed ID: 33757212
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.
Kalia LV
Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800
[TBL] [Abstract][Full Text] [Related]
19. Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels.
Montine TJ
Nat Rev Neurol; 2011 May; 7(6):308-9. PubMed ID: 21556033
[TBL] [Abstract][Full Text] [Related]
20. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
Kruse N; Schlossmacher MG; Schulz-Schaeffer WJ; Vanmechelen E; Vanderstichele H; El-Agnaf OM; Mollenhauer B
PLoS One; 2016; 11(4):e0153564. PubMed ID: 27116005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
